I have decided to probe deeper into the latter – and indeed, managed to dig up additional new info.
A Wall Street Journal news report on July 23 had highlighted that data from Israel had suggested Pfizer’s vaccine had become less effective in preventing infection of Covid-19, although it remains a robust bulwark against serious illness.
The findings, which are preliminary and based on a small sample, suggested that after two shots, the vaccine was 39% effective at reducing the risk of infection and 40% effective at reducing the risk of symptomatic disease during a period when the Delta variant dominated cases in Israel, according to the country’s Health Ministry.
I had also located a BMJ report (2021; 374 doi: https://doi.org/10.1136/bmj.n1920, published July 30, 2021) that mentioned that the efficacy of Pfizer’s Covid-19 vaccine fell from 96% to 84% over six months – after the second dose – according to Pfizer data that had been released. The preprint, which contained the latest data from the original clinical trial, found an average decline in vaccine efficacy of 6% every two months. Hmmm, this definitely raises concern!
This is supported by a “real world” study, conducted by the University of Oxford and the Office for National Statistics and published Thursday in a preprint that analyzed more than 3 million PCR tests from a random sample of people for a detailed picture of infection patterns as Delta became the dominant variant this year. And its findings showed that the Pfizer vaccine lost effectiveness in the first 90 days after the second jab.
And when vaccinated people did get infected with Delta, they were shown to have similar levels of virus in their bodies as those who hadn’t had shots. This suggests that vaccinating large portions of a population might not protect those who don’t get inoculated, casting doubt on the idea of achieving herd immunity.
Anyway, the third jab has already raised ethical concerns.
But not surprisingly, this has largely fallen on deaf ears.
No comments:
Post a Comment